Joel Lexchin
Joel Lexchin
Professor Emeritus, School of Health Policy & Management, York University
Verified email at
Cited by
Cited by
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
J Lexchin, LA Bero, B Djulbegovic, O Clark
bmj 326 (7400), 1167-1170, 2003
Industry sponsorship and research outcome
A Lundh, J Lexchin, B Mintzes, JB Schroll, L Bero
Cochrane database of systematic reviews, 2017
The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States
MA Gagnon, J Lexchin
Plos medicine 5 (1), e1, 2008
Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review
GK Spurling, PR Mansfield, BD Montgomery, J Lexchin, J Doust, ...
PLoS medicine 7 (10), e1000352, 2010
The cost of drug development: a systematic review
S Morgan, P Grootendorst, J Lexchin, C Cunningham, D Greyson
Health policy 100 (1), 4-17, 2011
How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA
B Mintzes, ML Barer, RL Kravitz, K Bassett, J Lexchin, A Kazanjian, ...
Cmaj 169 (5), 405-412, 2003
Interactions between physicians and the pharmaceutical industry: what does the literature say?
J Lexchin
CMAJ: Canadian Medical Association Journal 149 (10), 1401, 1993
Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey
B Mintzes, ML Barer, RL Kravitz, A Kazanjian, K Bassett, J Lexchin, ...
Bmj 324 (7332), 278-279, 2002
Pharmaceutical research and development: what do we get for all that money?
DW Light, JR Lexchin
Bmj 345, 2012
Physician awareness of drug cost: a systematic review
GM Allan, J Lexchin, N Wiebe
PLoS medicine 4 (9), e283, 2007
Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs
A Cassels, MA Hughes, C Cole, B Mintzes, J Lexchin, JP McCormack
Cmaj 168 (9), 1133-1137, 2003
The pharmaceutical industry as a medicines provider
D Henry, J Lexchin
The Lancet 360 (9345), 1590-1595, 2002
Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence
J Lexchin, P Grootendorst
International Journal of Health Services 34 (1), 101-122, 2004
Institutional corruption of pharmaceuticals and the myth of safe and effective drugs
DW Light, J Lexchin, JJ Darrow
Journal of Law, Medicine & Ethics 41 (3), 590-600, 2013
Bigger and better: how Pfizer redefined erectile dysfunction
J Lexchin
PLoS medicine 3 (4), e132, 2006
What information do physicians receive from pharmaceutical representatives?
J Lexchin
Canadian Family Physician 43, 941, 1997
Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications
J Lexchin
Science and engineering ethics 18 (2), 247-261, 2012
Drug promotion: what we know, what we have yet to learn: Reviews of materials in the WHO/HAI database on drug promotion
P Norris, A Herxheimer, J Lexchin, P Mansfield
Drug promotion: what we know, what we have yet to learn: reviews of …, 2005
Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments
M Roseman, K Milette, LA Bero, JC Coyne, J Lexchin, EH Turner, ...
Jama 305 (10), 1008-1017, 2011
Direct-to-consumer advertising of prescription drugs: the evidence says no
J Lexchin, B Mintzes
Journal of Public Policy & Marketing 21 (2), 194-201, 2002
The system can't perform the operation now. Try again later.
Articles 1–20